To examine the factors associated with total health care expenditures in newly diagnosed subjects with colorectal cancer (CRC) receiving systemic therapy. METHODS: Patients ages 18-63 years when newly diagnosed with CRC between January 1, 2005 and June 31, 2009 receiving systemic therapy were identified using a large, US-based administrative medical claims (MarketScan) database. At least 6 months of patient history prior to CRC diagnosis and at least 1-year post-index continuous enrollment was required. Patients were followed from initial CRC diagnosis (index date) to disenrollment or June 31, 2010. Chemotherapy and biologic treatments over time were analyzed to identify lines of therapy. Generalized linear regression models were used to estimate total medical expenditures (outcome variable) as a function of number of lines of therapy (key independent variable) and demographic/clinical covariates. The excess expenditures associated with additional lines of therapy were estimated as the difference between predicted medical expenditures for those with 1 st line of therapy versus 2 nd and 3 rd ϩ lines of therapy. RESULTS: A total of 5160 subjects were included with the majority being male (55%) and between ages 51-60 years (52%). After adjusting for demographic, and clinical covariates (comorbidities, metastasis development, and postindex CRC surgery and radiation) and follow-up days, the mean annualized total health care costs (Nϭ5,160) were predicted to be $67,902. Use of 2 nd line and 3 rd line ϩ therapies was associated with an annualized incremental costs of $11,662 [95% confidence interval (CI): $8, 876] and $43,313 (95% CI: $43,401), respectively. Age, gender, region, index year of diagnosis, post-index CRC surgery and/or radiation, development of metastasis (p-value Ͻ0.0001), presence of vascular comorbidities (p-valueϭ0.02), plan type (p-valueϭ0.04) and use of first line bevacizumab (p-valueϭ0.0002) were all associated with statistically significant increased likelihood of costs. CONCLUSIONS: Additional lines of therapy and use of first line biologics increased the cost of treatment substantially in CRC patients.
OBJECTIVES:
In the Brazilian private healthcare system, coverage for oral therapy is not mandatory. The association of lapatinib and capecitabine (LAP/CAP), both orally administered, is an effective combination for the treatment of patients with metastatic HER2 positive breast cancer (MBC-HER2ϩ) after progression to trastuzumab, but is not frequently used. The objective of this study was to evaluate treatment patterns and associated costs of MBC-HER2ϩ after progression to trastuzumab, under the perspective of the Brazilian private healthcare system and to calculate the economic impact associated with using LAP/CAP for this population. METHODS: Evidencias® database contains data related to around 3,000,000 lives covered by private health plans in Brazil. In this database, patients diagnosed with MBC-HER2ϩ and treated with chemotherapy after failure to trastuzumab were selected. For every patient, treatment costs were calculated considering drug costs only. Three cost scenarios were estimated: i) real-life chemotherapy (CT) used by patients; ii) hypothetical use of LAP/CAP; iii) hypothetical use of trastuzumab associated to capecitabine (TRAST/CAP). RESULTS: A total of 182 patients were included in the analysis. Average treatment duration was 10.5 weeks (95% CI: 8.9 -12.2). Twenty-two treatment protocols were identified after failure to trastuzumab, mainly: paclitaxel (27%), docetaxel (20%) and vinorelbine (14%). The average cost per patient were R$19,114.68, R$25,977.61 and R$39,437.26 , in the CT, and projected LAP/CAP and TRAST/CAP scenarios, respectively. Considering the results segmented by CT protocol, LAP/CAP costs were lower than CT for patients treated with paclitaxel associated or not to gemcitabine, among others. For all patients, projected costs with LAP/CAP were lower than TRAST/CAP. CONCLUSIONS: Patients treated with CT, eligible for treatment with LAP/CAP or TRAST/CAP, had lower treatment costs when compared to LAP/CAP or TRAST/CAP. In some specific CT combinations, however, LAP/CAP may result in lower costs, thus being considered an economically viable alternative.
PCN49 SEGMENTED MEDICAL COSTS OF SQUAMOUS CELL HEAD AND NECK CANCER: A PHARMACOECONOMIC ANALYSIS USING A PRIVATE INSURANCE DATABASE
Reveles IA 1 , Kreys ED 1 , Corral M 2 , Zhang Y 3 , Koeller JM 1 1 University of Texas at Austin, San Antonio, TX, USA, 2 Bristol-Myers Squibb Company, Plainsboro, NJ, USA, 3 Bristol-Myers Squibb Company, Pennington, NJ, USA OBJECTIVES: In 2004, average Medicare payments for treating squamous cell head and neck cancer (SCCHN) were an estimated $25,000 higher than matched controls. Specific diagnostic, treatment and end-of-life cost have not been delineated nor have the cost of newer biologic agents been factored into these estimates. We aim to determine the costs of diagnostic, treatment, and end-of-life phases of SCCHN and overall cost of treatment prior to and following cetuximab approval. METHODS: This was a retrospective analysis of the PharMetrics Choice insurance claims database. Patients Ն20 years of age with ICD-9-CM codes suggestive of advanced SCCHN diagnosed between March 1, 2003 and March 1, 2008 were included. Patients were divided by date of diagnosis prior to or following cetuximab approval (3/1/2006). Direct medical costs were calculated for specific phases (i.e., diagnostic, treatment, end-of-life) and overall. Patient characteristics are presented as descriptive statistics. Medical costs between phases and cohorts were compared using the Mann-Whitney U-Test. RESULTS: Overall, 366 patients met study criteria. Patients were predominately male (78.4%) with a median age of 57 years. Diagnostic costs were lower in pre-cetuximab ($5053) versus post-cetuximab ($6860) cohorts (pϭ0.028). Costs of treatment ($102,427 vs. $97,594; pϭ0.69) and end-of-life ($15,853 vs. $21,822; pϭ0.57) were similar among cohorts. Median total costs for pre-and post-cetuximab cohorts were $110, 099 and $111,156, respectively (pϭ0.82) . Treatment costs comprised the greatest percentage of total cost (89.3%) for SCCHN. Outpatient costs were the primary driver of treatment costs (median $19,248; 23%) followed by radiation therapy (median $15,691; 18%). Chemotherapy accounted for 2.6% (median $974) of treatment costs. In the post-cetuximab cohort, cetuximab was responsible for 5.7% and 4.4% of total and treatment costs, respectively. CONCLUSIONS: Compared to diagnosis and end-of-life phases, treatment is the primary driver of SCCHN costs, predominated by outpatient costs. Total costs were similar prior to and following cetuximab approval.
PCN50 A PILOT ASSESSMENT TO DETERMINE COST OF APHERESIS TREATMENT
Rebeira M 1 , Dranitsaris G 2 1 Genzyme, Mississauga, ON, Canada, 2 Augmentium Pharma Consulting, Toronto, ON, Canada OBJECTIVES: Autologous hematopoietic stem cell transplantation is considered to be standard care for patients with MM and NHL. For patients to proceed to stem cell transplantation, a sufficient number of stem cells must first be harvested through an apheresis procedure. Therapies such as plerixafor and filgrastim are used to enhance stem cell mobilization in these patients. The cost of apheresis, however, is difficult to obtain in a hospital setting in the Canadian context. METHODS: The main resource components for apheresis includes materials (plasma exchange sets, administration materials), medication, central line insertion, albumin 4% solution, laboratory tests, cryopreservation, nursing time and physician visits. Based on interviews conducted from a sample of nurses in the plasma exchange unit of University Health Network in Toronto, resource utilization was estimated. RESULTS: Costing for apheresis was done for a 4-day treatment protocol with different resource requirements for initial and subsequent sessions. It was determined that total costs of apheresis use for the first day and the subsequent 3 days were variable. It was estimated that over a four day treatment protocol, costs for materials, medication, central line insertion, albumin 4% solution, laboratory tests and nursing time amounted to $6035 (95% CI: $5291-$6780). The costs for the first session was estimated to be $1671 (95% CI: $$1,803-$1431). In addition, cyropresevation and storage costs of stem-cells were estimted to be $100 per day (UHN). Total costs therefore amounted to $6435per 4-day treatment protocol. CONCLUSIONS: This pilot study provides a reasonable estimate of resource utilization and costs incurred by hospitals in providing apheresis in Canada.
PCN51 COMPARING THE USE AND COST OF RADIOPHARMACEUTICALS IN PROSTATE CANCER PATIENTS WITH AND WITHOUT BONE METASTASIS
Seal B 1 , Sullivan SD 2 , Ramsey S 3 , Asche CV 4 , Shermock K 5 , Sarma S 6 , Farrelly E 7 , Eaddy M 7 1 Bayer HealthCare Pharmaceuticals, Inc., Pine Brook, NJ, USA, 2 University of Washington, Seattle, WA, USA, 3 Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, USA, 4 University of Illinois College of Medicine, Peoria, IL, USA, 5 Analysis by Design LLC, Columbia, MD, USA, 6 Independent Consultant, Wilmington, NC, USA, 7 Xcenda, Palm Harbor, FL, USA OBJECTIVES: The use of radiopharmaceuticals in oncology is expected to increase over the next few years. There are few studies, however, describing the cost associated with their use. This analysis compared the utilization and cost of patients treated in an outpatient or inpatient setting for prostate cancer (PCa) with bone metastasis (wBM) to those without bone metastasis (w/oBM). METHODS: Patients in the Premier Hospital Database between January 2006 and December 2010 treated in an inpatient or outpatient setting for PCa (ICD9 Codes 185 and 233.4) were included. Patients were required to be Ն40 years of age with no additional cancers. Patients were put into cohorts based on the presence of bone metastasis (ICD9 code 198.5 or the use of zoledronic acid or pamidronate disodium). Utilization of radiopharmaceuticals and PCa-specific treatments were compared, controlling for age, race, hospital, provider payer types, bed size, and admission source and type. Differences in treatments were assessed utilizing logistic regression, while differences in costs were analyzed using gamma distributed generalized linear models with a log link function. RESULTS: There were 23,747 hospitalizations for men wBM and 187,708 hospitalizations for men w/oBM. The mean age of men wBM was 73 years compared to 69 years for men w/oBM. The use of nuclear medicine-related PCa treatments was higher in patients w/oBM (4.8%) compared to wBM (1.2%). With overall costs of $9,728 in men with wBM and $7,405 (pϭ0.0006) in those w/oBM, nuclear medicine contributed only 1.2% and 5.2%, respectively (pϽ0.0001). Room and board contributed the greatest proportion of costs in men wBM (38.9%), while surgery (24.2%), room and board, and radiation (ϳ20% each) were the major contributors in men w/oBM. CONCLUSIONS: Although increasing in use, currently radiopharmaceuticals do not significantly contribute to the total cost of treating PCa patients in an inpatient or outpatient setting.
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